RELATED CONTENT
NEWS
- Roche's RoActemra is better than Abbot's Humira, says Scotland, but Zelboraf fails to impress
- Pfizer's arthritis contender tofacitinib faces possible US approval delay
- Expanded Japanese approval clears way to earlier stage Humira use
- Japan uptake of Simponi music to Mitsubishi Tanabe's ears
FEATURES
Other Informa Features

